
James Tumlin, MD, discusses RAINIER's proteinuria findings, dual APRIL/BAFF inhibition, safety, and the upcoming FDA decision.

James Tumlin, MD, is the president of NephroNet, director of research at Georgia Nephrology, and a professor of medicine in nephrology at Emory University School of Medicine.

James Tumlin, MD, discusses RAINIER's proteinuria findings, dual APRIL/BAFF inhibition, safety, and the upcoming FDA decision.

Tumlin discussed improvements in UPCR and Gd-IgA1 seen with povetacicept.

Tumlin reviews findings from a posthoc analysis of DUPLEX demonstrating sparsentan’s impact on partial remission, complete remission, and kidney failure.